SCHEMBL6793434

SCHEMBL6793434

Cc1nc(CC(=O)Nc2ccc(NC(=O)c3ccccc3-c3ccc(C(F)(F)F)cc3)cc2)cs1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.60
HTT P42858 1/20 0.60
MAPT P10636 3/20 0.52
TP53 P04637 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
GAA P10253 1/20 0.52
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
STAT1 P42224 2/20 0.51
KDM4E B2RXH2 1/20 0.51
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
SLC12A2 P55011 1/20 0.49
SLC12A5 Q9H2X9 1/20 0.49
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
MTTP P55157 6/20 0.47
APOB P04114 5/20 0.47
SMO Q99835 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6789887 0.89 LMNA (0.58) LMNAHTTMEN1KMT2AMTTP
SCHEMBL6794206 0.89 LMNA (0.60) LMNAHTTSMN1; SMN2MEN1KMT2A
SCHEMBL6794470 0.88 TP53 (0.54) LMNAHTTMAPTTP53SMN1; SMN2
SCHEMBL6794201 0.85 LMNA (0.56) LMNAHTTMAPTSMN1; SMN2KDM4E
SCHEMBL6799168 0.85 TP53 (0.49) LMNAMAPTTP53SMN1; SMN2GAA
SCHEMBL6795383 0.83 LMNA (0.52) LMNAHTTSMN1; SMN2MTTPAPOB
SCHEMBL6788870 0.82 LMNA (0.51) LMNAHTTMAPTSMN1; SMN2GAA
SCHEMBL6792281 0.81 SMO (0.62) LMNAHTTSMN1; SMN2MTTPAPOB
SCHEMBL7139254 0.81 LMNA (0.50) LMNAHTTMTTPAPOBSMO
SCHEMBL6787209 0.81 PTGS1 (0.51) LMNAHTTSMN1; SMN2MTTPAPOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed
EP-1326835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-07-16 EP disclosed
WO-2002028835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 LMNA 1239/4885HTT 2566/4885MAPT 4795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.